Posted by Michael Wonder on 06 Jun 2023
Esketamine hydrochloride for the treatment of adults with major depressive disorder at imminent risk of suicide
6 June 2023 - NICE is unable to make a recommendation on the use of esketamine hydrochloride (Spravato) for the treatment of adults with major depressive disorder at imminent risk of suicide because Janssen did not provide an evidence submission.
As usual, NICE will review this decision if Janssen decides to make a submission.
